Posts

Posted on

TCMD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Tactile Systems TechnologyShareholders of Class Action and Lead Plaintiff Deadline: November 30, 2020

TCMD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Tactile Systems TechnologyShareholders of Class Action and Lead Plaintiff Deadline: November 30, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tactile Systems Technology (“Tactile” or “the Company”) (NASDAQ: TCMD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Tactile securities between May 7, 2018 and June 8, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/tcmd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile’s medical devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile’s claims and criminal and civil liability; (4) Tactile’s revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants’ public statements, including its year-over-year revenue growth and the purported growth drivers, were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/tcmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Tactile you have until November 30, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

PT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Pintec Technology Holdings LimitedShareholders of Class Action and Lead Plaintiff Deadline: November 30, 2020

PT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Pintec Technology Holdings LimitedShareholders of Class Action and Lead Plaintiff Deadline: November 30, 2020

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Pintec Technology Holdings Limited (“Pintec” or “the Company”) (NASDAQ: PT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Pintec securities pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2018 initial public offering (“IPO” or the “Offering”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The Complaint alleges that the Registration Statement was false and misleading and omitted to state material facts, and specifically failed to disclose that: (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company’s financial results for fiscal 2017 and 2018 had been misstated; and (4) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/pt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Pintec you have until November 30, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Univest Securities, LLC. Announces Closing of $21 Million Follow-on Offering for its Ebang International Holdings Inc. (Nasdaq: EBON)

New York, Nov. 29, 2020 (GLOBE NEWSWIRE) — Univest Securities, LLC, a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $21 million follow-on offering (the “Offering”) for its Ebang International Holdings Inc. (Nasdaq: EBON) (the “Company”) to which Univest Securities, LLC. acted as the exclusive investment bank and sole-placement agent.

Univest Securities, LLC was able to raise in a follow-on offering for the sale of 4 million units of the 8 million units offered for sale by the Company, at a purchase price of $5.25 per unit, for aggregate gross proceeds of approximately $21.0 million. Each unit consists of one Class A ordinary share and one warrant to purchase one-half of one Class A ordinary share of the Company. Each two warrants have an exercise price per share of $5.50. The Company intends to use the net proceeds from the Offering primarily for development and application of blockchain technology into financial services, sourcing core intellectual properties relating to its businesses, corporate branding and marketing activities, and general corporate purposes, which may include working capital needs and other corporate uses.

Univest Securities, LLC. acted as the exclusive investment bank and placement agent to the Offering. Hunter Taubman Fischer & Li LLC acted as counsel to Univest in connection with the Offering.

The units are offered pursuant to the Company’s registration statement on Form F-1 (the “Form F-1”), as amended, which was originally filed with the SEC on October 23, 2020 and became effective on November 17, 2020. The units may be offered only by means of a prospectus forming a part of the effective registration statement. Copies of the final prospectus may be obtained at the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus may also be obtained by contacting Univest Securities, LLC at 375 Park Ave #1502, New York, NY 10152, by phone at (212) 343-8888 or by e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Univest Securities, LLC.

Registered with FINRA since 1994, Univest Securities, LLC. provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-added service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us.

About Ebang International Holdings Inc.

Ebang International Holdings Inc. is a leading Bitcoin mining machine producer in the global market in terms of computing power sold in 2019*, with strong application-specific integrated circuit (ASIC) chip design capability underpinned by nearly a decade of industry experience and expertise in the telecommunications business. With its licensed or registered entities in various jurisdictions, the Company seeks to launch a fully-licensed digital asset financial service platform to provide professional, convenient and innovative trading services. For more information, please visit https://ir.ebang.com.cn/.

*According to an industry report prepared by Frost & Sullivan in 2019


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s development plans and business outlook, which can be identified by terminology such as “may,” “will,” “expects,” “anticipates,” “aims,” “potential,” “future,” “intends,” “plans,” “believes,” “estimates,” “continue,” “likely to” and other similar expressions. Such statements are not historical facts, and are based upon the Company’s current beliefs, plans and expectations, and the current market and operating conditions. Forward-looking statements involve inherent known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance and achievements to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date indicated, and the Company undertakes no obligation to update or revise the information contained in any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.

Investor and Media Contact

Univest Securities, LLC.
Edric Guo
375 Park Avenue #1502
New York, NY 10152
Phone: (212) 343-8888
Email: [email protected]



Posted on

Univest Securities, LLC. Announces Closing of $10 Million Registered Direct Offering for its Client Tantech Holdings Ltd (Nasdaq: TANH)

New York, Nov. 29, 2020 (GLOBE NEWSWIRE) — Univest Securities, LLC, a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering with institutional investors raising approximately $10,000,000 for its client Tantech Holdings Ltd (Nasdaq: TANH) (the “Company”) to which Univest Securities, LLC. acted as the exclusive investment bank and sole-placement agent.

Univest Securities, LLC was able to raise approximately $10 million in gross proceeds from the sale of 6,060,608 of the Company’s common shares, priced at $1.65 per share, and registered warrants to purchase up to 2,754,820 common shares in a registered direct offering, and unregistered warrants to purchase up to 3,305,788 common shares in a concurrent private placement. Such registered and unregistered warrants are immediately exercisable, expire five years from the date of issuance and have an exercise price of $1.81 per share. The Company plans to use the net proceeds from the offering for working capital and general business purposes.

Univest Securities, LLC acted as the exclusive placement agent for the transaction and received unregistered warrants in connection with the offering exercisable for up to 363,637 common shares at $1.815 per share, which are exercisable at any time during the period commencing six months after the offering’s closing date through the third anniversary of the date of their issuance. Kaufman & Canoles PC acted as counsel to the issuer and Sullivan & Worcester LLP acted as counsel to the placement agent.

Such common shares and registered warrants were sold to the institutional investors pursuant to a prospectus supplement forming a part of the Company’s shelf registration statement on Form F-3 (File No. 333-248197), which was originally filed with the Securities and Exchange Commission (the “SEC”) on August 20, 2020 and was declared effective by the SEC on August 31, 2020.

A prospectus supplement to such registration statement which registers such common shares, registered warrants and the common shares underlying such registered warrants has been filed with the SEC on November 24, 2020. Copies of the prospectus supplement relating to such registered direct offering, together with the accompanying base prospectus, can be obtained at the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of the Company’s common shares or warrants in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Univest Securities, LLC.

Registered with FINRA since 1994, Univest Securities, LLC. provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-added service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us.

About Tantech Holdings Ltd

Established in 2001 and headquartered in Lishui City, Zhejiang Province, China, Tantech, together with its subsidiaries, is now, in addition to be a developer and manufacturer of bamboo-based charcoal, an innovative leader in the design, manufacture and distribution of electric vehicles. The Company has also invested in mining business in 2018 and 2019. For more information please visit: http://ir.tantech.cn.


Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor and Media Contact

Univest Securities, LLC.
Edric Guo
375 Park Avenue #1502
New York, NY 10152
Phone: (212) 343-8888
Email: [email protected]



Posted on

Philips Patient Management Solution keeps patients safe and personalizes care during COVID-19 at leading U.S. medical centers

November 29, 2020

  • Boston Medical Center, Yale New Haven Health and Lahey Hospital and Medical Center among the first to extend virtual care options enabling patients to remain safe during radiology exams, medical procedures, general visits, and more
  • Cloud-based, integrated digital communications help patients better prepare for appointments while reducing appointment no-shows

Amsterdam, the Netherlands –

Royal Philips
 (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it is working with leading medical centers to help respond to COVID-19 by increasing patients’ involvement in their care with the Philips Patient Management Solution. Outdated patient management practices can place excessive burden on staff, especially during COVID-19. Digital transformation during the pandemic is even more critical  to support staff with automation technologies that help unify and automate communications to patients in real-time.

Patient management is a critical element to help educate patients about available care, provide easier, safer, and timely access to that care, and to improve workflow efficiency for healthcare providers to manage patient encounters in a constrained economic and physical environment as the pandemic ensues. With studies showing that automated reminders can lead to a 41.5% reduction in patient no-shows [1] and a 67.0% reduction in poor patient preparation [2] in challenging diagnostic and interventional procedures, timely education and instructions to patients are essential as hospitals start rescheduling elective procedures.

The pause of elective and some chronic care with patient reluctance to visit hospitals and clinics during COVID-19 pandemic have contributed to a decrease in critical medical procedures, which can impact patient outcomes and put pressure on health system operations. Philips is committed to supporting healthcare providers with clinically optimized, intelligent diagnostic tools designed to increase productivity, improve workflow, and enhance patient and staff experience. Engaging patients through digital strategies is helping healthcare organizations enhance all their patient encounters including radiology scheduling, enabling remote screenings, guiding patients to resources, and providing real-time instructions in rapidly changing conditions.  

“Digital patient management solutions show a high level of maturity for healthcare organizations and enable them to keep patients safe with better personalized care during the pandemic,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “As a strategic partner to advance digital transformation, Philips has been certified to effectively educate and guide healthcare organizations as they progress through the Digtal Imaging Adoption Model (DIAM) maturity model stages. We are honored to team with these leading U.S. healthcare organizations in their commitment to recognizing patient engagement as a crucial factor in removing barriers to help improve patient care.”

Virtual contactless check-ins enhance patient and staff safety during COVID-19

Boston Medical Center (BMC) and Yale New Haven Health are using Philips Patient Management Solution to aid in patient communication during COVID-19, before, during, and after their appointments. BMC promotes telehealth consults for patients to stay connected with their care providers. The solution sends timely personalized reminders and helpful information about their upcoming telehealth appointments.

Before in-person appointments at the clinic, both institutions use the Patient Management Solution to screen patients using a digital survey to identify possible COVID-19 symptoms. Once the patient arrives for their appointment, the Patient Management’s Virtual Waiting Room functionality is leveraged to enable a contactless check-in process that eliminates the need for patients to congregate in a traditional waiting room setting. It integrates directly with EHR systems to ensure all aspects of the process smoothly embed into practice workflows where all patient communications are centrally stored.

The Patient Management Solution interoperates with the existing IT system to receive enrollment data and return feedback reports as a customer-facing dashboard. Patients scheduled for a radiology scan will receive personalized messaging to help them throughout the procedure. This includes screening for symptoms, protocol preparation instructions, appointment reminders, scan-specific education and expectation setting, last-minute tips, last-mile navigation, and follow-up and feedback survey.

COVID-19 screening for patients receiving in-hospital radiology scans

Lahey Hospital & Medical Center has been using Philips Patient Management Solution as one of their tools to identify patients who feel comfortable to receive care again. The platform facilitates screening for COVID-19 symptoms, getting information to patients about newly established safety protocols, and providing reassurance to put them at ease. Scheduling, access and clinical staff are thus able to focus their efforts on the patients who are most ready to return to the hospital for their care. 

Philips integrated radiology solutions spotlight at RSNA 2020

The Philips Patient Management Solution is being featured in the Philips virtual RSNA 2020 booth experience as an integral component of the new Radiology Workflow Suite to help improve patient and staff experience while enhancing clinical efficiency and operational excellence. The cloud-based solution previously known as Medumo, which was acquired by Philips in July of 2019, enables modern communication between care providers and patients and serves as a digital liaison to prepare patients for their appointments, help them show up on time, and continue to follow care plan instructions long after their visit or procedure. The solution interoperates with the EMR and can send automated messages through SMS, e-mail, voice, and paper mailings, complementing existing IT and clinical workflows. For more information, visit the Philips Patient Management Solution site. Visit Philips Live at RSNA 2020 for an advance look at Philips integrated workflow solutions to connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.

Philips’ triple duty of care

The COVID-19 pandemic continues to highlight how interconnected the world’s social, economic and environmental challenges are. Philips remains fully focused on delivering against its triple duty of care: meeting critical customer needs, safeguarding the health and safety of its employees, and ensuring business continuity. As a purpose-driven health technology company, Philips is applying its innovation strength to improve the health and well-being of people. The company is deeply committed to doing business responsibly and sustainably, recently setting out a range of challenging new environmental, social and governance targets.

[1] A Digital Preprocedure Instruction Program for Outpatient Colonoscopy, Richter JM et al. Telemedicine and e-Health VOL. 26, NO. 4 16 Apr 2020 https://doi.org/10.1089/tmj.2019.0050
[2] Nayor J, Feng A, Qazi T, Saltzman JR. Tu1044 Improved Patient Preparedness for Colonoscopy Using Automated Time-Release Reminders. Gastrointestinal endoscopy. 2018;87(6):AB507-AB508.3 https://pubmed.ncbi.nlm.nih.gov/30994519/

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : [email protected]
Twitter: @kathyoreilly

Silvie Casanova
Philips North America
Tel.: +1 781-879-0692
E-mail: [email protected]

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

 

Attachments



Posted on

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

UK government has now secured 7 million doses of mRNA-1273

Agreement reflects Moderna’s commitment to make its vaccine available in multiple countries

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the UK government for an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the United Kingdom beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. This confirmation comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines by establishing a broad portfolio of the most promising vaccines.

“We appreciate the collaboration with the UK government as with many other governments and other key partners around the world,” said Stéphane Bancel, Chief Executive Officer of Moderna. “For almost a decade, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. We are proud of the progress on mRNA-1273 we have made to date including the positive interim analysis from our Phase 3 COVE study.”

On November 16, Moderna announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

On October 27, 2020, Moderna received confirmation that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom started the rolling review process of mRNA-1273.

Moderna continues to scale up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021. The Company is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna. To learn more about Moderna’s work on mRNA-1273, visit www.modernatx.com/COVID19.

About mRNA-1273

mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. On May 29, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of mRNA-1273. On July 8, the Phase 2 study completed enrollment.

Results from the second interim analysis of the NIH-led Phase 1 study of mRNA-1273 in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On July 28, results from a non-human primate preclinical viral challenge study evaluating mRNA-1273 were published in The New England Journal of Medicine. On July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of mRNA-1273 was published in The New England Journal of Medicine. mRNA-1273 currently is not approved for use by any regulatory body.

BARDA is supporting the continued research and development of mRNA-1273 with $955 million in federal funding under Contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S. Department of Defense Contract No. W911QY-20-C-0100.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a potential vaccine (mRNA-1273) against the novel coronavirus, mRNA-1273’s efficacy and its ability to prevent infection or mitigate symptoms of COVID-19, the terms of the Company’s anticipated sale of mRNA-1273 to the government of the United Kingdom; the timing for the delivery of mRNA-1273 to the United Kingdom; plans to submit an application for regulatory approval for the distribution of mRNA-1273 to the MHRA; and plans for the manufacture of mRNA-1273 and the scale of anticipated production. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; despite having ongoing interactions with the FDA, MHRA or other regulatory agencies, the FDA, MHRA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

[email protected]

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

[email protected]

KEYWORDS: Massachusetts Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Posted on

GE Healthcare Expands AI, Digital and Imaging Solutions at #RSNA2020, Helping Shape Future of Healthcare in the COVID Era

GE Healthcare Expands AI, Digital and Imaging Solutions at #RSNA2020, Helping Shape Future of Healthcare in the COVID Era

CHICAGO–(BUSINESS WIRE)–
GE Healthcare today unveiled a slate of new intelligently efficient solutions to help clinicians solve today’s two-part challenge of delivering high quality care while managing greater capacity and workflow issues, exacerbated by the impact of COVID-19. Building on continuing investments in innovation and digital health momentum, GE Healthcare is expanding its AI offerings and Edison ecosystem, and also introducing breakthrough imaging innovations that will help shape the future of healthcare.

“COVID-19 has demonstrated the need for an adaptable and digitized healthcare system that empowers clinicians with next generation tools which would have otherwise taken years to develop and adopt quickly, accelerating changes that would have otherwise taken years to adopt,” said Kieran Murphy, president & CEO, GE Healthcare. “At GE Healthcare, we remain committed to driving innovation to achieve precision health and improve lives. This includes continued investment in our Edison intelligence portfolio, and also development of new imaging technologies to modernize standards of care.”

At this year’s virtual #RSNA2020, GE Healthcare is highlighting several new solutions that empower clinicians with future-looking technologies to drive efficiencies and improve patient outcomes, and address challenges related to COVID-19.

The Future is Now: raising the standard of care with intelligent efficiency

In an era when care is largely focused on the acute effects of COVID-19, healthcare’s challenges of cost, quality and access and provider pressure to do more with less remains. Add physician burnout – of which 64% of surveyed physicians said has intensified during the pandemici – and the need for efficiency has never been greater. “Like most heath systems, we were looking for system-wide efficiencies even before the pandemic hit,” said Laurie Sebastiano, MD, Section Chief of Ultrasound, St Luke’s University Health Network. “By working with GE Healthcare to standardize our fleet of ultrasound systems across our 12-hospital network, we will drive greater efficiency and consistency to our ultrasound users in the Vascular, Radiology and Echocardiography departments. Our new ultrasound equipment will help the technologist be more efficient because these machines are designed to streamline their activity and reduce clicks. Also, it will help the radiologist by bringing in some of the numbers that we routinely dictate right into our reports.”

  • Photon counting CT with Prismatic Sensors AB’s patented Deep Silicon detectors has the potential to further expand the clinical capabilities of traditional CT when fully developed, including the visualization of minute details of organ structures, improved tissue characterization, more accurate material density measurement (or quantification) and lower radiation doseii. GE Healthcare’s acquisition of Prismatic Sensors signifies the company’s continued investment in photon counting CT technology, which has the potential to significantly increase clinical performance for oncology, cardiology, neurology, and many other clinical CT applicationsii.
  • TrueFidelity for GSIiii has the potential to enhance traditional GSI images with reduced image noiseiv, improved contrast noise ratiov and low contrast detectabilityvi as well as preferred noise texturevii. In turn, the technology has the potential to enhance inherent GSI diagnostic benefits, such as lesion detection, characterization and artifact reduction.
  • Discovery MI Gen 2 is the is the only PET/CT system that brings together the sensitivityviii of digital detection with the innovative reconstruction technology available in CT: Deep Learning Image Reconstruction for TrueFidelity CT Images. Using a dedicated deep neural network to generate TrueFidelity CT Images, Discovery MI Gen 2 has the potential to improve reading confidence in a wide range of clinical applications such as head, whole body and cardiovascular, for patients of all ages.
  • AIR Recon DL is the MR industry’s first US FDA-cleared, deep learning-based image reconstruction technology that works across all anatomies. Available as an upgrade to installed base systems and forward production across all 1.5T and 3.0T scannersix, AIR Recon DL can help providers process the COVID-19 backlog faster without compromising image quality. Early adopters are seeing between 30-50 percent exam time reductions with AIR Recon DL, with higher signal-to-noise ratios (SNR) and higher resolution.
  • Allia IGS 7xis a completely redesigned image guided therapy suite designed to be an assistant focusing on ergonomics, ease-of-use and workflow efficiency. With just one click on the personalized interfaces, the users can access their essential functions to make it their room. Similarly, with the redesigned C-arm making the controls more accessible, the assistant will enable an optimized ergonomic setup for the user’s clinical needs, even in complex working positions at the head, neck or left side.
  • LOGIQ E10 Series are high-end radiology ultrasound systems that harness artificial intelligence (AI) technology to drive workflow productivity. This series includes the new LOGIQ E10 leadership ultrasound system for radiology with a full suite of advanced imaging tools and the new LOGIQ E10s ultrasound with multi-purpose capabilities in a scalable configuration. Built on the cutting-edge A to A digital platform, and using next generation cSound Architecture to automatically deliver images of exceptional uniformity, the LOGIQ E10 Series provides impressive imaging and full-featured versatility so clinicians can scan and care for a wide range of patients across a broad spectrum of conditions with speed and precision.
  • OEC 3Dxiis a new C-armdesigned to deliver 3D and 2D images presenting a large field of view to surgeons, integrating seamlessly into existing surgical workflows for enhanced surgical imaging precision and efficiency. OEC 3D features a 3D image reconstruction engine designed to present surgeons with high-resolution volume reconstructed CT-like images enabling surgeons to visualize exactly where they are operating in 3D for procedures where precision matters.
  • Command Centers empower every care team with their own real-time personal command center to optimize care progression, protocol compliance, staffing and so much more. GE’s Command Center software provides intuitive actionable information created from AI applied to integrated data from Electronic Medical Record modules and other systems.

Pandemic Disruption: tackling COVID-19 with trailblazing technologies

Whether defining the disease, determining a diagnosis, or observing the outcomes, COVID-19 is a disease of uncertainties. While the unknowns are still being studied and assessed, the need for health systems and healthcare providers to tackle and treat COVID-19 is both urgent and ubiquitous. Trailblazing technologies that launched prior to the pandemic, many of which are AI-powered, have proven to help the medical community better understand, triage, treat and manage COVID-19 and some of the resulting long-term health effects of the virus. “In the present times, AI is not a luxury, but a necessity for the high-quality patient care we’re providing in the hospital,” said Amit Gupta, MD, Modality Director of Diagnostic Radiography, University Hospitals Cleveland Medical Center. “As we operate with limited staff, scarce resources, and relying on residents’ support whenever we can, the team must make split second decisions in emergency situations. Critical Care Suite, the on-device AI solution that enables triage of critical conditions such as pneumothorax, helps our residents prioritize these types of patients.”

Here are a few examples of trailblazing technologies that are being used to tackle COVID-19:

  • Critical Care Suite 2.0xiifeatures a new AI algorithm to help clinicians assess Endotracheal Tube (ETT) placements, a necessary and important step when ventilating critically ill COVID-19 patients. The AI solution is one of five included in GE Healthcare’s Critical Care Suite 2.0, an industry-first collection of AI algorithms embedded on a mobile x-ray device for automated measurements, case prioritization and quality control that can help improve efficiency on the front lines.
  • VenueGo features an adaptable take-anywhere design and powerful AI-enabled auto tools that simplify complicated workflows to help the clinician care for patients at the point of care. From fast and automated assessments, like the AI-enhanced Auto B-line Tool that quickly calculates the overall lung score for triage decisions, to the fluid management and monitoring of pulmonary conditions including those associated with COVID-19xiii, Venue Go can help support the patient across all point of care areas and clinical spaces.
  • CT in a Boxxiv is an all-in-one portable CT solution available to pop up scan centers and hospitals to enable fast CT deployment using safe distancing measures and helping to minimize contact with potential COVID-19 cases. With more than 100 installed throughout the worldxiv, GE Healthcare’s CT in a Box solution is helping to provide accelerated access to CT imaging in situations requiring increased CT scansxv.
  • Vscan Extend handheld, pocket-sized ultrasound system empowers healthcare professionals to make focused assessments and accelerate treatment decisions at the point of care. In the COVID-19 environment, Vscan Extend can help manage patients with respiratory conditions offering a dual-probe system that is simple to use, easy cleanability and portability, and on-device applications that support lung and cardiovascular ultrasound exams.
  • Thoracic Care Suitexviharnesses the power of eight artificial intelligence (AI) algorithms from Lunit Insight CXR to help alleviate clinical strain due to COVID-19. The AI suite quickly analyzes chest x-ray findings and flags abnormalities to radiologists for review, including pneumonia, which may be indicative of COVID-19xvii as well as tuberculosis, lung nodules, and other radiological findings.
  • The new Ultra Edition release of Vivid products includes AI-based features which enable clinicians to quickly acquire more repeatable exams consistently and extends Vivid’s well-established strain-based functional assessment to the left atrium and right ventricle. Evidence of right heart dysfunction—especially right ventricular longitudinal strain on two-dimensional speckle-tracking echocardiography—is tightly linked to higher mortality among patients with COVID-19. Strain imaging is a particularly useful tool for gauging myocardial function in this setting.
  • The Mural Virtual Care Solution COVID-19 offering integrates data from multiple systems and devices into a single pane of glass to provide a real time (requires real time HL7 data feed from clinical devices), comprehensive view of patients’ status and to give hospitals the ability to extend clinical capabilities and resources by allowing visibility to at-risk and ventilated patients while minimizing exposure to staff.
  • CARESCAPE R860 is intuitively organized with workspace views so parameters and measurements, such as respiratory rate and tidal volume, as well as therapy controls are not buried in menus. Additionally, GE Healthcare has providedICU Ventilation User Resources to help clinicians respond to surges in ventilated COVID-19 patients and focus on delivering patient care.
  • Diagnostic Cardiology helps with the assessment of diagnostic ECG, which is critical in COVID-19 patients due to an increased incidence of arrhythmias and prolonged QT. Recognition of ST-elevated acute myocardial infarction needs to be done in the presence of a variety complicating factors including myocarditis, positive troponins and electrolyte abnormalities. See these clinical topics covered in Diagnostic ECG Clinical Insights.
  • Digital Expert is a remote technology training tool that can be used by healthcare providers to help navigate the challenges associated with a global pandemic by enabling virtual, live, face-to-face instructor-led interactive clinical training sessions using a mobile tablet. The technology provides individual users and entire departments with convenient access to training, enabling them to use equipment when it’s needed. Since COVID-19, Digital Expert has contributed to a 40 percent increase in calls made between customers and GE remote applications specialists and a 50 percent increase in the number of support hours provided to customersxviii. Digital Expert is currently available with Ultrasound, MR, X-Ray and Nuclear Workstation applications.

For more information on GE Healthcare and its intelligently efficient solutions, visit the company’s virtual RSNA booth or gehealthcare.com.

About GE Healthcare

GE Healthcare is the $16.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information

i Physician Income Drops, Burnout Spikes Globally in Pandemic, Medscape Medical News, Marcia Frellick, September 11, 2020.

ii Technology in development. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

iii TrueFidelity for GSI is 510k pending at FDA, not available sale in all regions.

iv Demonstrated in testing using the uniform section of the Catphan®600 with the CTP579 oval body annulus comparing pixel standard deviation in images reconstructed from the same raw data, at 0.625mm with DLIR‐H and ASiR‐V 50%.

v Demonstrated in testing using images of the CT ACR 464 Phantom (Gammex) and its 25 mm low contrast cylinder reconstructed from the same raw data with DLIR‐L, DILR-M, and DLIR-H and ASiR‐V 50%.

vi Evaluated using the body MITA CT IQ Low Contrast Phantom (CCT189, the Phantom Laboratory) with the CTP579 oval body annulus and a model observer with images reconstructed from the same raw data with DLIR‐H and ASiR‐V 50%.

vii As demonstrated in a clinical evaluation consisting of 40 cases and 5 physicians, where each case was reconstructed with both DLIR for GSI and ASiR-V and evaluated by 3 of the physicians. In 88% of the reads, DLIR for GSI’s noise texture was rated better than ASiR-V’s.

viii Discovery MI Gen 2 has the highest NEMA sensitivity in its class in the market, comparing with common PET/CT systems with same or similar AFOV (based on IMV’s Medical Information Division’s 2019 report as the manufacturers representing more than 90% of the US Installed Base).

ix AIR Recon DL is not yet CE marked for 1.5T. Product may not be available in all countries and regions and cannot be placed on the market or put into service until it has been made to comply with all required regulatory authorizations.

x Allia IGS 7 is not yet CE marked. Product may not be available in all countries and regions and cannot be placed on the market or put into service until it has been made to comply with all required regulatory authorizations.

xi 510(k) pending at the FDA. Not for sale. Not cleared or approved by other global regulators for commercial availability.

xii Critical Care Suite 2.0 is only available in the United States. Not cleared or approved by the FDA. Distributed in accordance with FDA imaging guidance regarding COVID-19 public health emergency.

xiii Accessed on 11/19/20: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/what-coronavirus-does-to-the-lungs.

xiv Available in select countries. Not available in all regions.

xv Rodgers, A et al. “The World Health Report 2002 Reducing Risks, Promoting Healthy Life.” World Health Report, World Health Organization, 2002, https://www.who.int/whr/2002/en/whr02_en.pdf?ua=1.

xvi Available in select CE Mark countries. Not available in all regions.

xvii Provisional Death Counts for Coronavirus Disease (COVID-19). Published June 12, 2020. Accessed June 12, 2020, from https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm.

xviii GE Healthcare Data on File.

Margaret Steinhafel

[email protected]

+1 608 381 8829

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Radiology Biotechnology Practice Management Insurance Health Infectious Diseases Hospitals Professional Services

MEDIA:

Logo
Logo
Posted on

TeraRecon Awarded Landmark Patent for Diagnostic Imaging Clinical Reporting with AI

New allowance includes continuous synchronization of AI findings between the image interpretation viewer, physician, and diagnostic report

DURHAM, N.C., Nov. 29, 2020 (GLOBE NEWSWIRE) — TeraRecon, the leading provider of AI-driven advanced visualization solutions, has been awarded an expansion of their patent-protected AI interoperability platform. Now encompassing an interactive, bi-directional, AI-informed reporting experience, this innovation utilizes physician activity and the work of a plurality of AI algorithms for the auto-generation of accurate, consistent, and actionable clinical reports.

This latest award recognizes and protects the innovation by extending the physician’s AI oversight to go beyond just a static view of the AI output to a fully interrogable and bi-directional interpretation experience within a pre-populated report. Physicians may be notified of unresolved findings to determine inclusion in the report. Further, this innovation unlocks unrealized value from the physician’s current reporting function to support downstream activities such as patient cohort selection, clinical report derived actions, care coordination, peer review, and optimization of the EHR.

“Healthcare is consistently striving for higher standards of performance and care – however, AI alone will not move the needle,” comments Jeff Sorenson, TeraRecon CEO. “How AI inputs are accessed, interacted with, and included in a physician’s diagnostic interpretation will require more than a unique algorithm application.” Sorenson continues, “For the clinician and their patients, this patent represents real forethought for AI insights to be integrated into workflows, trusted by the physician, and leveraged throughout an organization.”

TeraRecon has recently invested in expanding its relationships with PACS and other clinical solution partners, designing the next generation of advanced imaging workflows. These protected technologies are specifically designed to empower the customer’s existing PACS, archives, and EHR to deliver transformative imaging workflows that leverage real-world data and actionable insights to improve clinical outcomes. The full range of protected ideas and additional disclosures made in these TeraRecon AI patents can be accessed here.

TeraRecon’s end-to-end AI ecosystem, including the Eureka AI Results Explorer, AI interoperability platform, and Intuition™ advanced visualization technologies will be exhibited during the upcoming Radiological Society of North America’s 2020 Annual Scientific Virtual Session from Sunday, November 29th – Saturday, December 5th.

About TeraRecon: TeraRecon is a leader in medical advanced visualization and artificial intelligence solutions. Their flagship product, Intuition, is the 2020 KLAS category leader for advanced visualization and holds the number one market share for US 3D imaging. Recently acquired by SymphonyAI Group, TeraRecon is one of seven portfolio companies and is strategically focused on AI-driven innovation in healthcare. The company continues to innovate ahead of customer demand and has most recently developed sophisticated healthcare-focused artificial intelligence platform solutions unlike any in the world today. As a company with a 20-year history of innovation, TeraRecon’s mission is to continuously redefine medical advanced visualization by leveraging artificial intelligence to improve patient care. Website: www.terarecon.com

Contact Marketing at [email protected] and 650.372.1100

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0bf16cbc-b062-4da8-b334-d6d26c3450d8

 



Posted on

Aegon to sell its Central and Eastern European business to VIG

Aegon to sell its Central and Eastern European business to VIG

THE HAGUE, Netherlands–(BUSINESS WIRE)–Aegon has agreed to sell its insurance, pension and asset management business in Hungary, Poland, Romania and Turkey for EUR 830 million to Vienna Insurance Group AG Wiener Versicherung Gruppe (VIG).

“This transaction will simplify Aegon’s footprint and strengthen our balance sheet”, said Lard Friese, CEO of Aegon. “We are sharpening our strategic focus and are concentrating on those countries and business lines where Aegon can create most value. I would like to thank our employees in Hungary, Poland, Romania and Turkey for their significant contribution to Aegon over the years. We believe that our businesses will benefit greatly from the vast experience of VIG, a leading insurance group in the region.”

The proceeds amount to EUR 830 million and represent a multiple of 2.6 times the book value on June 30, 2020. This will result in an increase in IFRS equity of EUR 505 million of which EUR 362 million will be recognized as book gain based on the balance sheet position on June 30, 2020. The total net underlying earnings of Aegon’s businesses in Central and Eastern Europe amounted to EUR 54 million for 2019, implying a transaction multiple of 15 times net underlying earnings. As a result of the transaction, the Group Solvency II ratio is estimated to improve by approximately 8 percentage points.

The proceeds will be upstreamed to the Group and increase Aegon’s financial flexibility to execute on its strategic priorities, including deleveraging. On December 10, 2020, Aegon will provide an update on its strategy and financial targets at its virtual Capital Markets Day.

The transaction is subject to regulatory and antitrust approvals customary for transactions of this nature and is expected to close in the second half of 2021.

About Aegon

Aegon’s roots go back more than 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organizations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. More information on aegon.com.

Forward-looking statements

The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

  • Changes in general economic and/or governmental conditions, particularly in the United States, the Netherlands and the United Kingdom;
  • Changes in the performance of financial markets, including emerging markets, such as with regard to:

    • The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios;
    • The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and
    • The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;
  • Changes in the performance of Aegon’s investment portfolio and decline in ratings of Aegon’s counterparties;
  • Lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition;
  • Lowering of one or more of insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries;
  • The effect of the European Union’s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;
  • Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;
  • Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;
  • Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;
  • Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
  • Catastrophic events, either manmade or by nature, including by way of example acts of God, acts of terrorism, acts of war and pandemics, could result in material losses and significantly interrupt Aegon’s business;
  • The frequency and severity of insured loss events;
  • Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products;
  • Aegon’s projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;
  • Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
  • Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;
  • Customer responsiveness to both new products and distribution channels;
  • As Aegon’s operations support complex transactions and are highly dependent on the proper functioning of information technology, operational risks such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;
  • The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;
  • Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess cash and leverage ratio management initiatives;
  • Changes in the policies of central banks and/or governments;
  • Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
  • Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon’s products;
  • Consequences of an actual or potential break-up of the European monetary union in whole or in part, or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;
  • Changes in laws and regulations, particularly those affecting Aegon’s operations’ ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers;
  • Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;
  • Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); and
  • Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels.

This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Media relations

Dick Schiethart

+31(0) 70 344 8821

[email protected]

Investor relations

Jan Willem Weidema

+31(0) 70 344 8028

[email protected]

KEYWORDS: New York Netherlands North America United States United Kingdom Europe

INDUSTRY KEYWORDS: Consulting Professional Services Insurance Finance

MEDIA:

Logo
Logo
Posted on

Elbit Systems Awarded $96 Million Contract to Supply a Rotary-Wing Mission Training Center to a European Country

PR Newswire

HAIFA, Israel, Nov. 29, 2020 /PRNewswire/ — Elbit Systems Ltd. (NASDAQ: ESLT, TASE: ESLT) (“Elbit Systems” or “the Company”) announced today that it was awarded a contract valued at approximately $96 million to supply a European country with a Rotary-Wing Mission Training Center (“Rotary-Wing MTC”) and support services to train its Air Force, Army and Navy helicopter pilots and crews. The contract will be performed over a nine-year period, with an option to extend the maintenance services for an additional 10-year period.

The Rotary-Wing MTC is a networked multi-platform, mission-oriented, helicopter training center that will provide multi-level training for helicopter pilots and aircrews across the customer’s Armed Forces. The new training center will enable realistic simulated tactical training using all of the helicopter’s systems in a wide variety of mission scenarios. The Rotary-Wing MTC draws on the unique technologies and accumulated operational experience of the Company’s fighter aircraft tactical mission training centers.


Yoram Shmuely,
General Manager of Elbit Systems’ Aerospace Division commented: “This contract highlights the growing importance that Armed Forces place on leveraging proven technologies to enhance readiness while reducing costs.”


About Elbit Systems

Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance (“C4ISR”), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems.

For additional information, visit: https://elbitsystems.com/, follow us on Twitter or visit our official Facebook, Youtube and LinkedIn Channels.



Company Contact:



IR Contact:

 


Joseph Gaspar, Executive VP & CFO


Ehud Helft

Tel:  +972-4-8316663


Kenny Green


[email protected] 


GK Investor Relations

Tel: 1-646-201-9246


Rami Myerson,
Director, Investor Relations


[email protected]

Tel: +972-77-2948984


[email protected]

 


David Vaaknin,
VP, Brand & Corporate Communications

Tel: +972-77-2946691


[email protected] 

This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business.  Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings.  The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.’s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.

Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.  All other brand, product, service and process names appearing are the trademarks of their respective holders.  Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.

Cision View original content:http://www.prnewswire.com/news-releases/elbit-systems-awarded-96-million-contract-to-supply-a-rotary-wing-mission-training-center-to-a-european-country-301181303.html

SOURCE Elbit Systems Ltd.